Minapharm PharmaceuticalsCAI:MIPH -0.27%41 EBITDA Margin % is 19.70% as of Dec. 2025, which is 6% below its 10-year median of 20.86. GuruFocus rates CAI:MIPH with a GF Score™ of 41/100 and a GF Value™ of E£362.31 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 961 Drug Manufacturers companies, Minapharm Pharmaceuticals ranks better than 69.93% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Minapharm Pharmaceuticals EBITDA Margin % Related Terms
Minapharm Pharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAI:MIPH vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minapharm Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Minapharm Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minapharm Pharmaceuticals (CAI:MIPH) has a EBITDA Margin % of 19.70% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Minapharm Pharmaceuticals and its competitors. This is near median its historical median of 20.86. Over the past decade, Minapharm Pharmaceuticals' EBITDA Margin % has ranged from 12.33 to 29.70. According to the industry distribution chart, Minapharm Pharmaceuticals ranks #289 out of 961 companies in the Drug Manufacturers industry, placing it in the top 30.1%.
Is Minapharm Pharmaceuticals' EBITDA Margin % too high?
Minapharm Pharmaceuticals' current EBITDA Margin % of 19.70% is near median its 10-year median of 20.86. Over the past 10 years, this metric has ranged from a low of 12.33 to a high of 29.70. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Minapharm Pharmaceuticals' value of 19.70% is 57.7% above this industry median. Based on the distribution chart, Minapharm Pharmaceuticals ranks #289 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Minapharm Pharmaceuticals has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Minapharm Pharmaceuticals ranks #289 out of 961 companies for EBITDA Margin %. This puts Minapharm Pharmaceuticals in the upper half of its industry. The industry median EBITDA Margin % is 12.49. Minapharm Pharmaceuticals' value of 19.70% is 57.7% above this benchmark. Historically, Minapharm Pharmaceuticals' own EBITDA Margin % has ranged from 12.33 to 29.70 over the past decade. While the company's 10-year median is 20.86 vs. the industry median of 12.49, Minapharm Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Minapharm Pharmaceuticals's current EBITDA Margin % of 19.70% is 57.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Minapharm Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minapharm Pharmaceuticals's current EBITDA Margin % is 19.70%, which is near median its own 10-year median of 20.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£362.31, compared to a current price of E£698.08 — trading 92.7% above its estimated fair value. The current EBITDA Margin % is 19.70%, which is near median its 10-year median of 20.86 and 57.7% above the Drug Manufacturers industry median of 12.49. Minapharm Pharmaceuticals' overall GF Score™ is 41/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current EBITDA Margin % is 19.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued.
The current stock price of E£698.08 is trading 92.7% above its estimated GF Value™ of E£362.31.
GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CAI:MIPH:
EBITDA Margin %: 19.70% (near median its 10-year median of 20.86)
GF Value™: E£362.31 vs. price of E£698.08 (92.7% above fair value)
Industry Position: 57.7% above the Drug Manufacturers median (#289 of 961)
No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
41GF Score
Get the complete analysis for CAI:MIPH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:MIPH has been successfully added to your 
